The Immune Assessment of PD-1 Antibody Therapy in Tumor
Launched by QUANLI GAO · Nov 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a specific type of cancer treatment, called PD-1 antibody therapy, works by studying the immune system's response to it. Researchers will be reviewing past data on patients' immune functions along with their medical histories to understand how effective this treatment is for people with certain types of tumors.
To participate in this study, you must be at least 18 years old and have been diagnosed with a malignant tumor, which means a cancerous growth. Your medical records should be complete, and there must be information available about your immune function tests. If you meet these criteria, and if you're interested in how your body reacts to this type of therapy, you could be a good fit for this trial. Participants will have their previous medical data reviewed, but they will not need to take any new treatments as part of this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years.
- • 2. Pathologically confirmed malignant tumors.
- • 3. Complete medical records.
- • 4. Assessable immune function test data.
- Exclusion Criteria:
- • 1. Age \<18 years.
- • 2. No confirmed tumor pathology.
- • 3. Untraceable medical records.
- • 4. Non-assessable immune function tests.
About Quanli Gao
Quanli Gao is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to improving patient outcomes, the organization spearheads a range of clinical studies across various therapeutic areas, leveraging cutting-edge methodologies and technologies. Quanli Gao emphasizes collaboration with healthcare professionals and regulatory bodies to ensure rigorous adherence to ethical standards and regulatory compliance. By fostering a culture of scientific excellence and integrity, the sponsor aims to contribute significantly to the development of safe and effective treatments, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Trial Officials
Quanli Gao
Study Director
Henan Cancer Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported